NASDAQ: NAOVNanovibronix Inc Stock
$0.75+0.00 (+0%)
Updated Apr 25, 2024
NAOV Price
$0.75
Fair Value Price
N/A
Market Cap
$2.09M
52 Week Low
$0.70
52 Week High
$4.34
P/E
-0.35x
P/B
0.52x
P/S
0.88x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.28M
Earnings
-$3.71M
Gross Margin
67.3%
Operating Margin
-150.5%
Profit Margin
-162.5%
Debt to Equity
0.67
Operating Cash Flow
-$4M
Beta
0.51
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NAOV Overview
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NAOV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NAOV is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NAOV is good value based on its book value relative to its share price (0.52x), compared to the US Medical Devices industry average (3.71x)
P/B vs Industry Valuation
NAOV is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NAOV due diligence checks available for Premium users.
Be the first to know about important NAOV news, forecast changes, insider trades & much more!
NAOV News
Valuation
NAOV fair value
Fair Value of NAOV stock based on Discounted Cash Flow (DCF)
Price
$0.75
Fair Value
-$0.07
Undervalued by
1,234.83%
NAOV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NAOV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.35x
Industry
29.73x
Market
40.97x
NAOV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.52x
Industry
3.71x
NAOV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NAOV's financial health
Profit margin
Revenue
$1.2M
Net Income
-$813.0k
Profit Margin
-69.1%
NAOV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NAOV's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.7M
Liabilities
$2.7M
Debt to equity
0.67
NAOV's short-term assets ($6.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NAOV's short-term assets ($6.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NAOV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NAOV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$491.0k
Investing
$0.0
Financing
$0.0
NAOV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NAOV vs Medical Device Stocks
Nanovibronix Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.